Business Description
Biomm SA
SIC : 2834
ISIN : BRBIOMACNOR2
Total Employee Number:
130Compare
Compare
Traded in other countries / regions
BIOM3.Brazil IPO Date
2000-01-11Description
Biomm SA is a Brazilian biotechnology company focused on the development, production, and commercialization of biopharmaceuticals, particularly complex biologic drugs. Its main focus is recombinant human insulin and insulin analogs for the treatment of diabetes, developed through its own biotechnological processes. The company also has capabilities in producing active pharmaceutical ingredients and industrial enzymes, including enzymes used in biofuel production. Biomm serves the Brazilian pharmaceutical market, supplying biologic medicines to patients, healthcare providers, and distributors, and has pursued partnerships and technology-transfer agreements to manufacture and commercialize biosimilar products locally. Its revenue model centers on the sale of biopharmaceutical products, complemented by development and manufacturing activities. By producing high-complexity biologics domestically, the company aims to reduce Brazil's reliance on imported medicines and expand access to affordable treatments for chronic diseases such as diabetes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | 1.89 | |||||
Interest Coverage | 3.89 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.55 | |||||
Beneish M-Score | -0.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.6 | |||||
3-Year EPS without NRI Growth Rate | 66.2 | |||||
3-Year FCF Growth Rate | -4.5 | |||||
3-Year Book Growth Rate | 7.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.18 | |||||
9-Day RSI | 42.34 | |||||
14-Day RSI | 46.7 | |||||
3-1 Month Momentum % | -1.22 | |||||
6-1 Month Momentum % | -11.56 | |||||
12-1 Month Momentum % | -25.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.55 | |||||
Quick Ratio | 0.48 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 218.89 | |||||
Days Sales Outstanding | 58.36 | |||||
Days Payable | 118.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.6 | |||||
Shareholder Yield % | 2.11 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.06 | |||||
Operating Margin % | 10.61 | |||||
Net Margin % | 7.89 | |||||
EBITDA Margin % | 14.78 | |||||
FCF Margin % | -27.36 | |||||
OCF Margin % | -19.72 | |||||
ROE % | 10.22 | |||||
ROA % | 5.8 | |||||
ROIC % | 8.81 | |||||
3-Year ROIIC % | 60.38 | |||||
ROC (Joel Greenblatt) % | 15.01 | |||||
ROCE % | 12.25 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 26.08 | |||||
PE Ratio without NRI | 26.08 | |||||
PS Ratio | 2.4 | |||||
PB Ratio | 2.64 | |||||
Price-to-Tangible-Book | 3.31 | |||||
EV-to-EBIT | 20.6 | |||||
EV-to-EBITDA | 16.78 | |||||
EV-to-Revenue | 2.49 | |||||
EV-to-FCF | -10.08 | |||||
Price-to-GF-Value | 0.33 | |||||
Price-to-Graham-Number | 1.96 | |||||
| Price-to-Net-Current-Asset-Value | 10.98 | |||||
Earnings Yield (Greenblatt) % | 4.86 | |||||
FCF Yield % | -11.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomm SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 384.417 | ||
| EPS (TTM) (R$) | 0.283 | ||
| Beta | -0.2803 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.96 | ||
| Volatility % | 58.17 | ||
| 14-Day RSI | 46.7 | ||
| 14-Day ATR (R$) | 0.284622 | ||
| 20-Day SMA (R$) | 6.492 | ||
| 12-1 Month Momentum % | -25.71 | ||
| 52-Week Range (R$) | 4.82 - 10.39 | ||
| Shares Outstanding (Mil) | 136.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomm SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomm SA Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| 3:1 Stock Split | 2013-03-21 | -- |
Show
Entries
Biomm SA Frequently Asked Questions
What is Biomm SA(BSP:BIOM3)'s stock price today?
The current price of BSP:BIOM3 is R$6.26. The 52 week high of BSP:BIOM3 is R$10.39 and 52 week low is R$4.82.
When is next earnings date of Biomm SA(BSP:BIOM3)?
The next earnings date of Biomm SA(BSP:BIOM3) is .
Does Biomm SA(BSP:BIOM3) pay dividends? If so, how much?
Biomm SA(BSP:BIOM3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers